Cryoport Forms Strategic Relationship with Takeda’s BioLife Plasma Services
Cryoport plans to establish an integrated supply chain platform with BioLife Plasma Services to offer standardized cell therapy collection, processing and storage services in United States and Europe overtime
NASHVILLE, Tenn., September 8, 2022 /PRNewswire/ — Cryoport, Inc. (Nasdaq: CYRX) (“Cryoport” or the “Company”), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced that it has entered into a strategic relationship with BioLife Plasma Services , part of global biopharmaceutical company Takeda, to provide consistent, high-quality cellular starting material for use in the manufacture of life-saving cell therapies.
By combining BioLife Plasma Services’ proficiency in apheresis collection and their donation center infrastructure with Cryoport’s world-class life science capabilities and expertise in supply chain solutions temperature-controlled for the biopharmaceutical industry, the companies aim to establish an integrated and standardized apheresis collection. , processing and delivery solution for cell therapies. Importantly, the new platform will leverage the cryo-processing expertise of Cell Matters, which Cryoport acquired at the end July 2022.
Today, the availability of cell therapy assets is limited by lack of flexibility in donation planning, lack of standardization in collection and processing, and inherent challenges in ensuring compliance with Good Manufacturing Process regulations ( GMP). This new relationship, which will facilitate strict compliance with applicable GMP regulations, aims to shorten processing and logistics times and standardize collections, contracts and equipment, enabling researchers and developers to accelerate therapy programs. cellular. Increased access to apheresis, with efficient, scalable and reliable end-to-end processes, will benefit not only donors and patients, but also manufacturers and providers of these life-saving therapies.
Commenting on the agreement, Jerell SheltonCEO of Cryoport, said, “This strategic relationship with BioLife Plasma Services is a great example of how our world-class expertise in providing supply chain solutions to the life sciences industry and our expansion into new geographies and service offerings, such as bioservices and cryo-processing, creates exciting new opportunities. Our goal is to streamline the complex processes required to treat an increasing number of patients with today’s most advanced cell therapies while ensuring the highest standards of quality and safety.
As a first step, the two companies will establish a new operating platform in Houston, TXwhich will provide end-to-end collection, processing and distribution services by bringing together new Houston-global supply chain hub with local BioLife Plasma Services donation facilities. Under the direction of trained BioLife employees with in-depth knowledge of the fields of cell therapy and apheresis, cell collections will be performed by dedicated cell collection personnel in a designated space within the BioLife Plasma Donation Center. Services. Effective immediately, the companies will cooperate in strategic sales and marketing activities, with the aim of attracting and creating a pipeline of customer demand that will utilize supply. This will provide the opportunity to define the infrastructure and capital commitments needed to scale and potentially expand the offering across United States and Europe overtime.
Hema TallmanGlobal Head of BioLife Plasma Services, added, “Cell therapy is one of the most promising areas of development in healthcare today. This agreement reflects the transformative leadership of BioLife Plasma Services and Takeda and their commitment to bringing better health and a brighter future to patients around the world. As we constantly explore how we might address unmet patient needs, this relationship will optimize the use of our first-class facilities, state-of-the-art capabilities and skilled workforce of healthcare professionals and technicians. . leader in flexible cryogenic logistics solutions, uniquely positions both companies to implement and potentially scale a market-leading end-to-end offering across our global network of donation centers that could enable more patients to benefit of these life-saving therapies. »
Operations are expected to begin in 2022 with apheresis programming and collections to be launched by BioLife Plasma Services in the Houston Region. Cryoport will provide cold chain solutions including packaging, logistics, data management, consulting, program management, cryoprocessing and bioservices.
About Cryoport, Inc.
Cryoport, Inc. (Nasdaq: CYRX), headquartered in Nashville, TN, is a global leader in temperature-controlled supply chain solutions for the life sciences industry, supporting lifesaving cell and gene therapies across the clinical and commercial spectrum. With 38 strategic locations spanning the Americas, EMEA (Europethe Middle East and Africa) and APAC (Asia Pacific), Cryoport’s global platform provides critical solutions, services and products to biopharma, reproductive medicine and animal health customers worldwide. In addition to its standard supply chain solutions, Cryoport is the world’s largest manufacturer of cryogenic systems and one of the largest life science-focused specialty couriers. From July 31, 2022Cryoport has supported nine commercial cell and gene therapies and 626 regenerative medicine clinical trials in more than 150 countries, including 81 Phase 3 trials.
Statements contained in this press release that are not purely historical, including statements regarding the Company’s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions, are statements forward-looking statements within the meaning of the Private Securities Litigation Reform Act. of 1995. Such forward-looking statements include, but are not limited to, those relating to the industry, businesses, long-term growth prospects, plans, strategy, acquisitions, future financial results and financial condition of the Company, such as the outlook and financial condition of the Company. forecasts for full-year 2022 revenues and related factors that are expected to generate revenues, projected trends in the markets in which the Company operates, the Company’s intention to expand its global manufacturing capabilities, the planned the Company of a new global supply chain center in Paris, repurchases of the Company’s common stock and regulatory approvals regarding the Company’s customer products. It is important to note that the actual results of the Company could differ materially from those of these forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, including as a result of the COVID-19 pandemic and its variations, supply chain constraints, inflationary pressures and the effects of foreign currency fluctuations, product market trends, variations in the Company’s cash flows, market acceptance risks and technical development. The Company’s business could be affected by a number of other factors, including the risk factors discussed in the Company’s Securities and Exchange Commission (“SEC”) reports, including, but not limit, the Company’s annual report on Form 10-K for the year ended December 31, 2021, its quarterly reports on Form 10-Q filed with the SEC in 2022, as well as in its subsequent filings with the SEC. The forward-looking statements contained in this press release speak only as of the date hereof and the Company cautions investors not to place undue reliance on such forward-looking statements. Except as required by law, the Company disclaims any obligation and does not undertake to update or revise any forward-looking statements contained in this press release.
SOURCE Cryoport, Inc.